Literature DB >> 25493227

New concepts in axillary management of breast cancer.

Can Atalay1.   

Abstract

In the last decades, surgical treatment of breast cancer has evolved from more extensive procedures like radical mastectomy to less invasive breast conserving surgery. Similarly, surgical management of axilla has enormously changed from routine axillary dissection to sentinel lymph node biopsy. Traditional surgical approach to the axilla in case of sentinel lymph node negativity is to avoid completion axillary dissection. However, surgeons even avoid performing axillary dissection in selected patients with positive sentinel lymph node in clinical practice depending on the recent randomized controlled studies supporting this concept. All of the recent changes in the management of positive axilla necessitate surgeons to refresh their knowledge on this challenging topic.

Entities:  

Keywords:  Axilla; Breast; Cancer; Sentinel lymph node

Year:  2014        PMID: 25493227      PMCID: PMC4259951          DOI: 10.5306/wjco.v5.i5.895

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  29 in total

1.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer.

Authors:  G Cserni; D Gregori; F Merletti; A Sapino; M P Mano; A Ponti; S Sandrucci; B Baltás; G Bussolati
Journal:  Br J Surg       Date:  2004-10       Impact factor: 6.939

3.  Sentinel lymphadenectomy in breast cancer.

Authors:  A E Giuliano; R C Jones; M Brennan; R Statman
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

4.  Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.

Authors:  Manon J Pepels; Maaike de Boer; Peter Bult; Jos A van Dijck; Carolien H van Deurzen; Marian B Menke-Pluymers; Paul J van Diest; George F Borm; Vivianne C G Tjan-Heijnen
Journal:  Ann Surg       Date:  2012-01       Impact factor: 12.969

5.  Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN.

Authors:  R F D van la Parra; P G M Peer; M F Ernst; K Bosscha
Journal:  Eur J Surg Oncol       Date:  2011-02-12       Impact factor: 4.424

6.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

7.  The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.

Authors:  Arpana M Naik; Jane Fey; Mary Gemignani; Alexandra Heerdt; Leslie Montgomery; Jeanne Petrek; Elisa Port; Virgilio Sacchini; Lisa Sclafani; Kimberly VanZee; Raquel Wagman; Patrick I Borgen; Hiram S Cody
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

8.  Micrometastases or isolated tumor cells and the outcome of breast cancer.

Authors:  Maaike de Boer; Carolien H M van Deurzen; Jos A A M van Dijck; George F Borm; Paul J van Diest; Eddy M M Adang; Johan W R Nortier; Emiel J T Rutgers; Caroline Seynaeve; Marian B E Menke-Pluymers; Peter Bult; Vivianne C G Tjan-Heijnen
Journal:  N Engl J Med       Date:  2009-08-13       Impact factor: 91.245

9.  Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up.

Authors:  Christine Louis-Sylvestre; Krishna Clough; Bernard Asselain; Jacques René Vilcoq; Remy Jacques Salmon; François Campana; Alain Fourquet
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

10.  Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Nora M Hansen; Kevin P Bethke; Alfred W Rademaker; Clifford Y Ko; David P Winchester; David J Winchester
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

View more
  5 in total

1.  Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer.

Authors:  Mai Kasahara; Makoto Nagahara; Tsuyoshi Nakagawa; Toshiaki Ishikawa; Takanobu Sato; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Oncol Lett       Date:  2016-07-07       Impact factor: 2.967

2.  Analysis of factors influencing postoperative drainage time in breast cancer.

Authors:  Quanyi Long; Jia Zhang; Jiahao Qi; Yuan Fan; Hongjiang Li
Journal:  Gland Surg       Date:  2021-12

3.  Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.

Authors:  Florian Ebner; Achim Wöckel; Wolfgang Janni; Rolf Kreienberg; Lukas Schwentner; Manfred Wischnewsky
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-24       Impact factor: 4.553

4.  Validation of Memorial Sloan Kettering Cancer Center nomogram to detect non-sentinel lymph node metastases in a United Kingdom cohort.

Authors:  A Syed; S Eleti; V Kumar; A Ahmad; H Thomas
Journal:  G Chir       Date:  2018 Jan-Feb

5.  Axillary Lymph Node Dissection for Breast Cancer: Efficacy and Complication in Developing Countries.

Authors:  Mohaned O Abass; Mohamed D A Gismalla; Ahmed A Alsheikh; Moawia M A Elhassan
Journal:  J Glob Oncol       Date:  2018-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.